A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is a multicenter, open-label, observational, post marketing surveillance program to collect information on the use of NutropinAq® in adults suffering from Growth Hormone Deficiency in Germany, Italy, and United Kingdom
Incidence of serious adverse events [ Time Frame: when reported ]
Secondary Outcome Measures
Incidence of targeted adverse events, including adrenal insufficiency, arthritis, carpal tunnel syndrome, intracranial hypertension, new onset and recurrence of leukemia & tumor, pancreatitis, peripheral edema requiring medical intervention and death [ Time Frame: when reported ]
Incidence of intercurrent cardiovascular events [ Time Frame: when reported ]
Incidence of fractures [ Time Frame: when reported ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients treated with NutropinAq in the specialised adult endocrinology centres in Germany, Italy, and UK.
Patients with Growth Hormone Deficiency
Patients treated with NutropinAq®
Patients having completed growth (fused epiphyses)
Bone Diseases, Developmental
Bone Diseases, Endocrine
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs